Together, our results implicate that the influx of MDM with high checkpoint expression and T-cell subsets in the TME distinguishes metastatic melanoma with a favorable response to anti-PD-1 treatment and improved survival. This evidence concerns the gene PDCD1 and metastatic melanoma.